Lax-A Senna

Natural health product licensed in Canada

Other names: Lax-A Night, Lax-A Sen, Sennatab
Licence holder: PendoPharm, Division of/de Pharmascience Inc.
NPN or DIN-HM: 02068109
Status: Active licence
Licence date: 3 October 2007
Revision date: 5 February 2025
Form: Comprimé
Route of administration: Orale
Application type: DIN de transition

If this product were sold in France

No point flagged by the rules we apply.

A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.

Composition

Medicinal composition not provided.

Non-medicinal ingredients

Eau purifiée, FD&C Blue No.2, Dioxyde de silicium colloïdal, FD & C Jaune no. 6, Jaune D & C No. 10, (p)-hydroxybenzoate de méthyle, Lactose monohydrate, Hypromellose, sulfate sodique de lauryle, Stéarate de magnésium, Cellulose, microcristalline

Recommended doses in Canada

Population	Age	Quantity per serving	Frequency
Adultes et enfants	minimum: 11 years	minimum: 2 Comprimé ; maximum: 4 Comprimé	1 Tous les jours

Uses authorised in Canada

Text supplied in English because no French text is available.

For comfortable relief of occasional constipation. For comfortable and overnight relief of occasional constipation. Stimulant laxative. Short-term relief of occasional constipation. Lax-A Senna relieves constipation by increasing the rate of colonic motility, enhancing colonic transit, and inhibiting water and electrolyte secretion. Promotes bowel movement by direct action on the large intestine. Lax-A Senna provides laxative effects by its twofold action: (1) it acts on the motility of the large intestine by stimulating peristaltic contractions and inhibiting local contractions, which results in an accelerated colonic transit and thus in a reduction of fluid absorption, and (2) it influences fluid and electrolyte absorption and secretion by the colon by stimulating mucus and chloride secretion, which increase fluid secretion.

A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.